Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel
NASDAQ:VCNX

Vaccinex 8/10/2026 Earnings Report

Vaccinex logo
$1.12 0.00 (0.00%)
As of 08/5/2026
Profile

Vaccinex EPS Results

Actual EPS
N/A
Consensus EPS
-$73.04
Beat/Miss
N/A
One Year Ago EPS
N/A

Vaccinex Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.63 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Vaccinex Announcement Details

Quarter
Date
8/10/2026
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Vaccinex Earnings Headlines

Vaccinex to Report New Biomarker Data and Plans for Phase 2B Clinical Trial of Pepinemab in AD at the Alzheimer's Association International Conference in London on July 13, 2026
July 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/08/3324070/34858/en/vaccinex-to-report-new-biomarker-data-and-plans-for-phase-2b-clinical-trial-of-pepinemab-in-ad-at-the-alzheimer-s-association-international-conference-in-london-on-july-13-2026.html
Vaccinex, Inc. Reports Financial Results for Year Ended December 31, 2025
April 29, 2026  |  quiverquant.comQ
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.tc pixel
August 7 at 1:00 AM  |  Porter & Company (Ad)
Vaccinex Reports 2025 Annual Financial Results
April 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/30/3284388/34858/en/vaccinex-reports-2025-annual-financial-results.html
Vaccinex Inc.
April 10, 2026  |  barrons.comhttps://www.barrons.com/market-data/stocks/vcnx/company-people
Vaccinex announces $60M revenue sharing agreement with PDV
December 23, 2025  |  msn.comhttps://www.msn.com/en-us/money/other/vaccinex-announces-60m-revenue-sharing-agreement-with-pdv/ar-AA1SUmDZ
See More Vaccinex Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Vaccinex? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vaccinex and other key companies, straight to your email.

About Vaccinex

Vaccinex (NASDAQ:VCNX) is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting oncology and neurodegenerative diseases. Headquartered in Rochester, New York, Vaccinex harnesses its proprietary human antibody platform to modulate the semaphorin 4D (SEMA4D) pathway, a mechanism implicated in tumor immune evasion and neuroinflammatory processes. Its lead asset, pepinemab (VX15/2503), is an investigational monoclonal antibody designed to bind and block SEMA4D, thereby promoting immune cell infiltration in tumors and supporting neural repair in degenerative disorders.

In oncology, Vaccinex has advanced pepinemab through Phase 2 trials in solid tumors and hematologic malignancies, exploring its potential to enhance the efficacy of established checkpoint inhibitors. Concurrently, the company is conducting a pivotal Phase 2/3 study in early Huntington’s disease, evaluating pepinemab’s ability to slow cognitive and functional decline. Vaccinex’s pipeline also includes preclinical candidates targeting additional indications driven by SEMA4D biology, supported by collaborations with academic institutions and industry partners.

Founded in the early 2000s, Vaccinex operates primarily in the United States, where it manages its clinical development, regulatory affairs and manufacturing activities. Under the leadership of President and CEO David Hallal, the company remains focused on advancing its strategic pipeline toward key regulatory milestones and potential commercialization, leveraging partnerships to broaden its research and development capabilities.

View Vaccinex Profile
Earnings Tools